Latest Breaking News On - Pfizer inc nasdaq - Page 1 : comparemela.com

BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB 1 5-adapted COVID-19 Vaccine in the European Union

BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB 1 5-adapted COVID-19 Vaccine in the European Union
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAlbert bourlaUgur sahinFosun pharmaEuropean commission for the omicronRoche groupEuropean medicines agencyEuropean unionDrug administrationEuropean commissionPfizer inc nasdaqWorld health organizationCommittee for medicinal products human useExchange commissionMedicinal products

BioNTech SE: Pfizer and BioNTech Receive U S FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based

United statesSylke maasFosun pharmaCenters for diseasePfizer inc nasdaqWorld health organizationDrug administrationDrug administration fastExchange commissionPfizer incRoche groupWorld health organization coronavirusFast track designationNorthern hemisphereWorld healthEmergency use authorization

BioNTech SE: Pfizer and BioNTech Receive U S FDA Emergency Use Authorization for Omicron BA 4/BA 5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary seriesConsistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children

United statesUnited kingdomMark wietechaSylke maasBiontech covidAlbert bourlaUgur sahinFosun pharmaAmerican academy of pediatricsUs centers for diseasePfizer incEuropean unionUs department of health human servicesCenters for diseasePfizer inc nasdaqDrug administration

BioNTech SE: Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a

United statesUnited kingdomSylke maasFosun pharmaPfizer inc nasdaqDrug administrationExchange commissionPfizer incEuropean unionRoche groupMarketing authorization holderEmergency use authorizationCoronavirus diseasePrescribing informationVaccination providersCaregivers fact sheets

BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA 4/BA 5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

NEW YORK and MAINZ, GERMANY, November 10, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY Original/Omicron BA.4/BA.5

United statesUnited kingdomSylke maasFosun pharmaPfizer inc nasdaqEuropean commissionExchange commissionEuropean unionEuropean medicines agencyRoche groupCommittee for medicinal products human useMedicinal productsHuman useMarketing authorization holderProduct characteristicsPackage leaflet